Skip to main content
Top
Published in: International Journal of Hematology 4/2017

01-04-2017 | Case Report

Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment

Authors: Mariagrazia Porru, Antonella Mameli, Maria E. Cianchetti, Mario Musu, Paola Schirru, Maria F. Ruberto, Doris Barcellona, Francesco Marongiu

Published in: International Journal of Hematology | Issue 4/2017

Login to get access

Abstract

Dabigatran is an oral, direct thrombin inhibitor approved by international regulatory agencies for stroke prevention in patients with paroxysmal or persistent non-rheumatic atrial fibrillation (AF). The benefits of dabigatran are widely described, but its use in the geriatric population is not without risk. Chronic kidney disease is a common comorbidity with AF, and thus frequent checks of renal function in elderly patients are recommended. We report a case of dabigatran intoxication in an elderly man affected by heart failure and worsening renal function, who developed acute hepatitis and coma, which was successfully treated with continuous veno-venous hemodiafiltration. Although extracorporeal therapy has been suggested as a strategy for clearing dabigatran during acute bleeding, this approach may be useful in other dabigatran-related, life-threatening conditions, such as that described in this report.
Literature
2.
go back to reference Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. RE-LYinvestigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–83. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. RE-LYinvestigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–83.
3.
go back to reference Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel group, single-centre study. Clin Pharmacokinet. 2010;49:259–68.CrossRefPubMed Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel group, single-centre study. Clin Pharmacokinet. 2010;49:259–68.CrossRefPubMed
4.
go back to reference Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A. Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost. 2012;18:549–50.CrossRefPubMed Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A. Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost. 2012;18:549–50.CrossRefPubMed
5.
go back to reference van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.CrossRefPubMed van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.CrossRefPubMed
6.
go back to reference Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace. 2013;15:625–51.CrossRefPubMed Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace. 2013;15:625–51.CrossRefPubMed
7.
go back to reference Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–60.CrossRef Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–60.CrossRef
8.
go back to reference Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.CrossRefPubMed Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.CrossRefPubMed
9.
go back to reference Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–99.CrossRefPubMed Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–99.CrossRefPubMed
10.
go back to reference Bouchard J, Ghannoum M, Bernier-Jean A, Williamson D, Kershaw G, Weatherburn C, et al. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Clin Toxicol (Phila). 2015;53:156–63.CrossRef Bouchard J, Ghannoum M, Bernier-Jean A, Williamson D, Kershaw G, Weatherburn C, et al. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Clin Toxicol (Phila). 2015;53:156–63.CrossRef
11.
go back to reference Claisse G, Delavenne X, Masson I, Maillard N, Alamartine E, Mariat C. Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. Clin Kidney J. 2015;8:199–201.CrossRefPubMedPubMedCentral Claisse G, Delavenne X, Masson I, Maillard N, Alamartine E, Mariat C. Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. Clin Kidney J. 2015;8:199–201.CrossRefPubMedPubMedCentral
12.
go back to reference Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61:487–9.CrossRefPubMed Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61:487–9.CrossRefPubMed
13.
go back to reference Artunc F, Muehlbacher T, Baumann D, Birschmann I, Kuhn J, Heyne N, et al. Removal of dabigatran is superior by sustained low efficient dialysis (SLED) compared to intermittent hemodialysis. Blood Purif. 2015;39:331–2.CrossRefPubMed Artunc F, Muehlbacher T, Baumann D, Birschmann I, Kuhn J, Heyne N, et al. Removal of dabigatran is superior by sustained low efficient dialysis (SLED) compared to intermittent hemodialysis. Blood Purif. 2015;39:331–2.CrossRefPubMed
14.
go back to reference Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol. 2013;8:1533–9.CrossRefPubMedPubMedCentral Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol. 2013;8:1533–9.CrossRefPubMedPubMedCentral
Metadata
Title
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment
Authors
Mariagrazia Porru
Antonella Mameli
Maria E. Cianchetti
Mario Musu
Paola Schirru
Maria F. Ruberto
Doris Barcellona
Francesco Marongiu
Publication date
01-04-2017
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2158-0

Other articles of this Issue 4/2017

International Journal of Hematology 4/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine